AI documentation tools in European public health: what administrators need to know

Artificial intelligence (AI)-assisted documentation tools can meaningfully reduce the time European municipal health workers spend on clinical notes — but deploying them means navigating the General Data Protection Regulation (GDPR), the EU AI Act, medical device rules, and public procurement law before a pilot even begins.

Artificial intelligence (AI)-assisted documentation tools can meaningfully reduce the time European municipal health workers spend on clinical notes, but deploying them means navigating the General Data Protection Regulation (GDPR), the EU AI Act, medical device rules, and public procurement law before a pilot even begins.

What these tools do, and what they don't

AI-assisted documentation tools, sometimes called AI medical assistants or ambient documentation tools, capture spoken clinical encounters and convert them into structured clinical notes. A community health worker conducts a patient visit as normal. The tool listens, transcribes, and generates a draft note. The clinician then reviews and approves that note before it enters the medical record system.

In a municipal public health setting, this looks quite different from general practice surgeries or hospital wards. Community health programmes are typically population-level and non-acute, covering home nursing visits, mental health follow-ups, rehabilitation sessions, health visitor appointments, and chronic disease management. Documentation in these settings is high in volume, repetitive in structure, and spread across a dispersed workforce that often has no consistent administrative support. That combination is the core problem these tools address.

The practical value is time recovery. A six-week pilot in Farsund Municipality, Norway, involving twenty employees across three care teams, found that total daily documentation time fell from around three hours to ten to fifteen minutes. A separate large-scale observational study across Capio/Ramsay Santé facilities in Sweden, evaluating an AI medical assistant across 375,000 clinical notes, found consistent reductions in self-reported documentation time across multiple care levels; that study was preregistered and followed SQUIRE reporting guidelines, which set standards for quality improvement research. Both studies rely substantially on self-reported outcomes, so administrators should build objective measurement into their own pilot design where possible.

These tools transcribe and structure what a clinician says and does during an encounter. They don't diagnose, prescribe, or generate clinical recommendations. That distinction has direct regulatory consequences, and it's worth being precise about it before any regulatory conversation begins.

The regulatory frameworks that apply

Four frameworks intersect when a municipality evaluates an AI documentation tool. Understanding where each one applies, and which obligations fall on the vendor versus the organisation deploying the tool, is the foundation for any defensible procurement decision.

EU AI Act. The EU AI Act came into force in August 2024 and sets out a tiered risk classification system. High-risk systems in healthcare are those used for diagnosis, treatment decisions, or clinical decision support that directly influences patient care outcomes. A documentation tool that captures and structures clinical encounters without generating clinical recommendations sits in a different position: its primary function is administrative. Administrators should ask vendors for a written risk classification rationale and verify that the tool includes no decision-support features that would shift its classification. The Act also introduces transparency obligations: where AI systems are present during patient appointments, patients must be informed.

GDPR. Of the four frameworks, GDPR creates the most immediate pre-pilot obligations and the most consequential ongoing ones. Health data is special category data under Article 9. Processing it requires a lawful basis under Article 6 and an additional condition under Article 9, most commonly explicit consent, or processing necessary for the provision of health or social care under Article 9(2)(h). Before any pilot, municipalities must carry out a Data Protection Impact Assessment (DPIA): under Article 35, this is mandatory when processing special category health data using new technology. A signed data processing agreement with the vendor, required under Article 28, must be in place before any data is shared. During the pilot, data minimisation applies: audio recordings shouldn't be kept beyond the period needed for transcription, and the vendor must not use patient data for model training without explicit authorisation. After deployment, the municipality must maintain records of processing activities under Article 30 and be able to fulfil data subject rights including access and erasure. Staff whose voices are captured are also data subjects; their rights apply, and the municipality must establish a lawful basis for processing their data too.

EU Medical Device Regulation (MDR). The MDR applies to software intended for a medical purpose, including diagnosis, prevention, monitoring, prediction, prognosis, treatment, or alleviation of disease. A tool whose sole function is transcribing and structuring clinical encounters, without generating any output that influences clinical decisions, generally falls outside medical device classification. Features such as flagging clinical abnormalities, suggesting diagnoses, or prompting treatment considerations may change that. Administrators should ask vendors for a written MDR classification rationale, verify whether the tool holds a CE mark as a medical device and under which classification, and confirm that any CE marking applies to the version being piloted. The Swedish multi-site study is worth noting here because the tool it evaluated was CE-marked, a useful reference point for what vendor certification looks like in practice.

Public procurement law. AI documentation tools procured by European municipal public health bodies are subject to the EU public procurement framework under Directive 2014/24/EU. For sub-central public bodies, the current services contract threshold is €215,000 net of VAT, though this figure is revised periodically and should be checked against the most recent Commission Delegated Regulation. Contracts above this threshold require a formal tender procedure published in the Official Journal of the EU. Below threshold, national procurement rules still apply. Technical specifications should describe functional and compliance requirements rather than a single vendor's product, which the directive prohibits. Contract terms should include clear data ownership provisions, exit provisions that allow data retrieval without prohibitive cost or technical lock-in, and audit rights that let the municipality verify compliance during the contract term.

Data residency: what to confirm before sharing any patient data

For most European public health bodies, processing health data outside the EU or European Economic Area (EEA) is not permissible under their national data protection frameworks, regardless of what the GDPR technically permits through transfer mechanisms. Several EU Member States impose stricter requirements than the GDPR baseline, and many municipal procurement policies require explicit confirmation that data is held within the EU.

Before piloting, administrators should get written confirmation from the vendor on four points: where audio data is processed at the point of transcription; where structured notes are stored and for how long; whether any sub-processors are involved and where they're located; and whether any data is transferred outside the EU or EEA at any stage of the processing pipeline, including for model training or quality assurance. Vendors using infrastructure in the United States, United Kingdom, or other non-EEA countries should specify the legal transfer mechanism in use, for example Standard Contractual Clauses, and confirm that no health data is processed on servers outside the EEA as part of normal operations.

The European Health Data Space, which entered into force in 2025, introduces additional infrastructure for cross-border health data use. Administrators should keep an eye on how it interacts with national data residency requirements as implementation progresses, particularly for municipalities running cross-border health programmes.

How to structure a low-risk pilot

A well-scoped pilot reduces regulatory exposure, generates usable evidence, and gives you a solid foundation for a defensible deployment decision. Limit scope to a specific care team, programme, or site: a single community nursing team is far more manageable than a municipality-wide rollout. Six to twelve weeks is enough to generate meaningful data; the Farsund pilot ran for six weeks and produced clear, quantifiable outcomes.

Define success criteria before the pilot begins, not after. Relevant metrics include documentation time per visit, staff-reported usability scores, error rates in generated notes, and patient feedback on the experience of having the tool present. Written sign-off is needed from the Data Protection Officer (confirming the DPIA is complete), the procurement lead (confirming the contract and data processing agreement are in place), and the clinical lead (confirming the clinical governance framework is agreed). Prepare a clear, plain-language explanation for patients about the tool's presence and purpose, available in the languages spoken by the patient population. Define what happens to data, notes, and access rights if the pilot is discontinued or the vendor relationship ends before full deployment.

The WHO/Europe report published in April 2026, the first comprehensive review across all 27 EU Member States, identifies workforce training and AI literacy as among the most significant factors in successful AI deployment. All participating staff should understand how the tool works, what their review responsibilities are, and how to report errors or concerns before any data is processed.

What to verify independently when assessing a vendor

The following should be verified independently, not accepted on the basis of marketing materials. Each point covers a distinct compliance area, and vendors should be able to provide documentation rather than assurances.

• ISO 27001 certification: request the current certificate and verify that its scope covers the systems used to process health data

• GDPR data processing agreement: review it against the Article 28 requirements before any data is shared

• EU AI Act conformity documentation: ask for the vendor's written risk classification assessment and any conformity documentation required under their classification tier

• Medical device status: if the tool holds a CE mark as a medical device, request the Declaration of Conformity and verify the notified body involved

• Model training transparency: ask explicitly whether patient data from your deployment will be used to train or fine-tune the model, what the legal basis is, and whether you can opt out

• Evidence from comparable settings: request references or published evidence from deployments in public sector or municipal health settings in Europe; peer-reviewed or preregistered studies carry more weight than internal case studies

• Language capability: confirm the tool performs accurately in the specific language or languages used by your clinical staff, including regional dialects or clinical terminology specific to your national health system

A peer-reviewed study examining health technology procurement in Swedish municipalities found that municipalities use evidence inconsistently when making procurement and evaluation decisions, and that existing national guidance doesn't give municipalities enough support to make well-evidenced choices. That finding points to something worth stating plainly: building internal evaluation capacity matters more than any single piece of vendor-provided evidence. A crossover randomised controlled trial evaluating AI-assisted clinical coding in Sweden and Norway, conducted by the Norwegian Centre for E-Health Research, provides a useful methodological reference for rigorous evaluation study design, though clinical coding assessment differs from evaluating ambient documentation tools.

Building internal alignment across procurement, legal, and clinical teams

AI documentation tools sit at the intersection of at least four regulatory frameworks and typically need sign-off from procurement, legal and data protection, and clinical leadership. These functions don't always work closely together in municipal settings, and each has a different primary concern.

Start with the Data Protection Officer. The DPIA is a prerequisite for any pilot involving special category health data, and bringing the DPO in before selecting a vendor avoids the common situation where a preferred vendor is identified and then fails the data protection assessment. When making the clinical case, frame it in operational terms: clinical leads are more likely to engage with a proposal built around reducing the paperwork load and recovering time than one framed around technology adoption. The evidence from Farsund and the Swedish multi-site study provides concrete figures that can anchor that conversation.

Procurement teams may not be familiar with the EU AI Act or MDR. A clear summary of which obligations apply, and which are the vendor's responsibility versus the municipality's, helps them write specifications and evaluate bids accurately. Every decision to proceed, pause, or exclude a vendor should be recorded with a rationale; in a regulated procurement environment, the audit trail matters.

The OECD has noted that most EU health systems lack dedicated funding structures for AI tools and has highlighted collective purchasing models, such as five Dutch hospitals pooling resources to evaluate AI systems, as a way to support more equitable deployment. Municipalities considering joint procurement with neighbouring authorities or regional health bodies should assess whether this model could cut evaluation costs and strengthen their negotiating position. Norway's national AI plan for healthcare, which includes real-world deployments such as Vestre Viken Health Trust's AI rollout serving 22 municipalities and around 500,000 people, shows that AI documentation tools are being taken seriously at a policy level, a useful reference point for administrators building internal support for evaluation.

Frequently asked questions

▶ What do AI-assisted documentation tools actually do during a community health visit?

The tool listens, transcribes, and produces a draft note. The clinician approves it before it enters the medical record system. Nothing is diagnosed or prescribed. Practically, this means the visit itself runs as normal and the paperwork happens in the background.

▶ What evidence exists for time savings in municipal public health settings?

The Farsund and Capio/Ramsay Santé findings are covered in the body above. The more useful planning question is how to replicate that rigour locally: build objective time-logging into your pilot from day one rather than relying solely on staff recall after the fact.

▶ Does the EU AI Act classify documentation tools as high-risk?

A pure transcription tool is unlikely to be classified as high-risk, but classification depends on what the specific version being piloted actually does. Ask the vendor for their written classification rationale, then have your legal team review it rather than accepting the conclusion at face value.

▶ What GDPR obligations apply before a pilot begins?

The DPIA and the Article 28 data processing agreement are both prerequisites, as covered above. One detail worth adding: staff whose voices are captured are also data subjects. The municipality needs a documented lawful basis for processing their data too, which is easy to overlook when the focus is on patient data.

▶ How do municipalities confirm that patient data stays within the EU?

Get written confirmation covering audio processing, note storage, sub-processors, and any transfers outside the EEA at any pipeline stage. The four specific questions to put to vendors are listed in the body above. Ask for the answers in writing before signing anything.

▶ When does the EU Medical Device Regulation apply to an AI documentation tool?

The boundary is whether the tool's output influences a clinical decision. Transcription alone generally falls outside MDR scope. The practical risk is that vendors add features over time, such as abnormality flags, that shift the classification. Contract terms should require the vendor to notify you before releasing any update that changes the tool's MDR status.

▶ What procurement rules apply when a municipality buys an AI documentation tool?

The threshold and tender requirements under Directive 2014/24/EU are covered in the body above. One practical addition: write technical specifications around functional and compliance requirements from the start. Specifications drafted around a preferred vendor's product are prohibited and can expose the procurement to challenge.

▶ Who is responsible if an AI-generated clinical note contains an error?

The clinician who approves the note carries clinical and legal responsibility. Before the pilot, confirm with the vendor that approval logs are retained, that each note is clearly attributed to the approving clinician, and that the contract states this responsibility explicitly rather than leaving it implied.

▶ How should a municipality structure a low-risk pilot?

The core structure is covered in the body above. The single most common failure point is defining success criteria after the pilot ends rather than before it begins. Agree on specific, measurable thresholds for documentation time, error rates, and usability scores at the sign-off stage, so the evaluation decision isn't made on impressions.

▶ What should administrators verify independently when assessing a vendor?

The checklist is in the body above. The underlying principle is that each item requires documentation rather than a verbal assurance. If a vendor cannot produce a current ISO 27001 certificate, a written AI Act classification rationale, and a clear answer on model training within a reasonable timeframe, that is itself a signal worth weighing.